Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

65.63 +1.37 (+2.13%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc ADR

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
59 60 Next >
Top 5 Health Care Stocks That May Rally
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Johnson & Johnson's Upcoming Lung Cancer Data Could Offer Another Blockbuster Opportunity, Says Analyst
Via Benzinga
TEZSPIRE® approved for self-administration in the US with a new pre-filled pen
From AstraZeneca
Via Business Wire
3 No-Brainer Dividend Stocks to Buy Hand Over Fist in 2023
These healthcare titans are poised for a strong showing in 2023 and beyond. 
Via The Motley Fool
These 2 Healthcare Stocks Have Doubled in 2023
Wouldn’t it be great if a stock had a bulkier capitalization and 2x potential? This is rare but possible for these two small-mid health care stocks. 
Via MarketBeat
AZN Stock Under Pressure
Shares in UK-headquartered AstraZeneca are back under heavy selling pressure on Monday as the stock extends recent losses. 
Via Talk Markets
The Top Healthcare Stocks to Buy With $100
Don't overlook these big-name foreign healthcare stocks. 
Via The Motley Fool
$1,000 Invested In 4 Of The 5 Vaccine Developers Back When WHO Declared COVID-19 An Emergency Yielded Returns
The COVID-19 pandemic emerged in 2019 in China and spread to the rest of the globe in early 2020. Since then, the virus has caused more than 6.8 million deaths. 
Via Benzinga
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a 
Via MarketBeat
Exposures Product Safety
Could This Vaccine Become Sanofi's Latest Blockbuster?
This vaccine candidate could be approved in newborns and infants later this year. 
Via The Motley Fool
Could This Be Novartis' Next Blockbuster Medicine?
The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug. 
Via The Motley Fool
7 Dividend Stocks to Buy for a Stable Income Stream
These are the dividend stocks to buy for a regular income stream and potential capital gains as these stocks trade at attractive valuations. 
Via InvestorPlace
Mergers and Acquisitions in 2023 Off To A Strong Start
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road. 
Via MarketBeat
Exposures Product Safety
Is Johnson & Johnson Still a Good Dividend Stock to Buy?
A disappointing fourth-quarter performance has some investors worried about the giant healthcare conglomerate's outlook. 
Via The Motley Fool
AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.
From AstraZeneca
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paya Holdings Inc. (Nasdaq – PAYA), CinCor Pharma, Inc. (Nasdaq – CINC), Albireo (Nasdaq – ALBO), Duck Creek Technologies (Nasdaq - DCT)
From Brodsky & Smith LLC
Via GlobeNewswire
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
After years of lab failures, the companies could crack open a multibillion-dollar market. 
Via Investor's Business Daily
AstraZeneca’s Next “Wonder Drug”
Enhertu is an antibody-drug conjugate, a type of therapy designed to do minimal damage to healthy, non-cancerous cells. Wall Street analysts believe that Enhertu has the potential to become a key... 
Via Talk Markets
Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical Trials
EQNX::TICKER_START (NASDAQ:TCBP),(NASDAQ:CRDF),(NASDAQ:CYAD),(NASDAQ:RIGL),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19 Product Safety
AbbVie Stock: Dividend King ABBV Overview
Via MarketBeat
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
From HUTCHMED (China) Limited
Via GlobeNewswire
Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices
Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch... 
Via Talk Markets
The Viral “Tripledemic” Opportunity
Between Covid, the flu, and RSV, investors in over-the-counter consumer pharmaceutical companies might be wondering if now is a logical time to up their holdings in the companies that make cold and flu... 
Via Talk Markets
3 Growth Stocks Poised for Huge Gains in 2023
These big pharmaceuticals are poised for back-to-back big years. 
Via The Motley Fool
Why These Two Biotech Stocks Blasted Higher This Week
There's nothing like a big-premium buyout to send a company's share price to the moon. 
Via The Motley Fool
Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review
Sharp Tesla price cuts and some notable earnings were in focus. 
Via Investor's Business Daily
Could This New Drug Launch Be a Hit for Viatris?
Viatris and Kindeva Drug Delivery could soon launch a generic version of AstraZeneca's Symbicort. 
Via The Motley Fool
AstraZeneca's New Asthma Treatment for Adults Gets Green Light from FDA
Via Benzinga
AIRSUPRA™ (PT027) approved in the US for asthma
From AstraZeneca
Via Business Wire
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.